Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Profit After Tax (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Profit After Tax for 9 consecutive years, with -$128.5 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 12.02% to -$128.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$512.5 million through Dec 2025, down 21.23% year-over-year, with the annual reading at -$512.5 million for FY2025, 21.23% down from the prior year.
  • Profit After Tax for Q4 2025 was -$128.5 million at Denali Therapeutics, down from -$126.9 million in the prior quarter.
  • The five-year high for Profit After Tax was $183.4 million in Q2 2023, with the low at -$133.0 million in Q1 2025.
  • Average Profit After Tax over 5 years is -$84.9 million, with a median of -$100.6 million recorded in 2023.
  • The sharpest move saw Profit After Tax surged 411.91% in 2023, then crashed 154.0% in 2024.
  • Over 5 years, Profit After Tax stood at -$75.3 million in 2021, then crashed by 31.11% to -$98.7 million in 2022, then decreased by 21.07% to -$119.5 million in 2023, then rose by 3.95% to -$114.8 million in 2024, then dropped by 12.02% to -$128.5 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$128.5 million, -$126.9 million, and -$124.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.